Peter Attia· MD
804 carriers once they have the disease are reluctant or less likely to benefit from the supplementation compared to non-carriers
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
804 carriers once they have the disease are reluctant or less likely to benefit from the supplementation compared to non-carriers
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
But what was interesting to me and also very discouraging was that people with ApoE4 allele did not have those benefits.